

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Kurt M. Kessler

Examiner: Celia C. Cha

Application No.: 09/760,590

Art Unit: 1625

Filed: 01/16/01

Title: **Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

July 25, 2002
Date of Deposit

Signature

Commissioner for Patents
Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

☒ No additional fee is required.

The fee has been calculated as shown below.

| (1) | (2) CLAIMS REMAINING AFTER AMENDMENT* | (3) | (4) HIGHEST NUMBER PREVIOUSLY PAID FOR** / *** | (5) PRESENT EXTRA | (6) RATE | (7) ADDITIONAL FEE |
|---|--|-------|---|-------------------------|-------------|--------------------------|
| TOTAL CLAIMS | 10 | MINUS | 12 | 0 | 18.00 | 0.00 |
| INDEPENDENT CLAIMS | 6 | MINUS | 7 | 0 | 84.00 | 0.00 |
| MULTI-DEPENDENT CLAIMS(S), Per Application (280.00) | | | | | | 0.00 |
| TOTAL AMENDMENT FEE FOR THIS AMENDMENT | | | | | | \$0.00 |

* If the entry in Column 2 is less than the entry in Column 4, write "0" in Column 5.

** If the "Highest Number Previously Paid For" in Total Claims is less than 20, write "20" in this space.

*** If the "Highest Number Previously Paid For" in (Independent Claims) is less than 3, write "3" in this space.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. 1.16 which may be required by this paper or credit any overpayment to Account No. 18-1982. Two duplicate copies of this paper are enclosed.

Respectfully submitted,

Lawrence L. Martin
Lawrence L. Martin, Reg. No. 46,902
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4803
Telefax (908) 231-2626

Aventis Docket No. HMR2041 US NP1

PATENT

Docket No.: HMR2041 US NP1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of
Kurt M. Kessler

Examiner: Celia C. Chang

Art Unit: 1625

Serial No.: 09/760,590

Filed: 01/16/01

Title: Ethanol Solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4R-(3S-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

Date of Deposit

Signature

RECEIVED

AUG 06 2002

TECH CENTER 1600/2000

AMENDMENT PURSUANT TO 37 C.F.R. § 1.121 (b) and 37 C.F.R. § 1.121 (c)
AND REPLY PURSUANT TO 37 C.F.R. § 1.111

Box Non-Fee Amendment

Commissioner for Patents

Washington, D.C. 20231

Sir:

This is in response to the outstanding Office Action, dated February 1, 2002, paper number 7, for which a response is due by May 1, 2002, in the above-identified patent application. A petition for three-month extension of time is enclosed herewith to make this response timely. Entry of the following Amendments and Remarks is respectfully requested.